If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies.
about
Practical application of the neuroregenerative properties of ketamine: real world treatment experienceOptimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical PracticePharmacological approaches to the challenge of treatment-resistant depressionTargeting the glutamatergic system to treat major depressive disorder: rationale and progress to dateHomer1/mGluR5 activity moderates vulnerability to chronic social stressLight therapy for non-seasonal depression: systematic review and meta-analysisUse of SSRI and SNRI Antidepressants during Pregnancy: A Population-Based Study from Denmark, Iceland, Norway and SwedenPrevalence of treatment-resistant depression in primary care: cross-sectional data.Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis.Effectiveness of cognitive behavioural therapy augmentation in major depression treatment (ECAM study): study protocol for a randomised clinical trial.Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment.Stimulants for depression: On the up and up?Assessing the roles of stimulants/stimulant-like drugs and dopamine-agonists in the treatment of bipolar depression.Combination of agomelatine and bupropion for treatment-resistant depression: results from a chart review study including a matched control group.Development and validation of a high-performance liquid chromatography-tandem mass spectrometric method for simultaneous determination of bupropion, quetiapine and escitalopram in human plasma.Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design.RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response.Real-world determinants of adjunctive antipsychotic prescribing for patients with major depressive disorder and inadequate response to antidepressants: a case review studyTreatment-resistant depression: therapeutic trends, challenges, and future directions.Somatic drugs for psychiatric diseases: aspirin or simvastatin for depression?Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.Major depressive disorder: new clinical, neurobiological, and treatment perspectives.Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care.Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy studyTreating major depression with yoga: A prospective, randomized, controlled pilot trialMedical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy.Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder.Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studiesTrazodone Addition to Paroxetine and Mirtazapine in a Patient with Treatment-Resistant Depression: The Pros and Cons of Combining Three Antidepressants.A Breathing-Based Meditation Intervention for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Randomized Pilot Study.What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment.The hidden third: improving outcome in treatment-resistant depression.Psychostimulants in moderate to severe affective disorder: a systematic review of randomized controlled trials.Management of chronic depressive patients with residual symptoms.Treatment resistant depression: strategies for primary care.Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: a European perspective.Weight considerations in psychotropic drug prescribing and switching.
P2860
Q26748766-02C47FA3-5313-4ECC-848E-A8ADDE0EF718Q26797416-257C11E4-3FC9-4264-84AF-EEC8660D20E6Q26798241-C8FCF76D-520C-46D9-A3A6-A80041C42122Q27004490-27CC0913-171C-4E23-AE9E-21D39230DD0AQ27311111-97F36336-39C2-4F9C-BD2A-43186B3B3405Q28080214-97141AC7-4AFC-439F-A0EC-8BB7ABCBE149Q28551620-944EA271-01A0-4E2D-A558-B547D1A3B7FDQ30718433-04F7F84D-7CE8-49D0-AACA-A2C8BFE5DE3AQ33625345-21D4AB34-685A-4D5C-B569-C19AA8290285Q33814867-ECF43590-7597-45B4-A377-86A7C387AC8BQ34397198-B2F0D898-0F04-49B8-A8B4-D22D44D801EEQ34417713-18652E44-E59E-4881-923E-43BA9C1483F9Q34515266-6A638F35-3890-4DB9-93C0-02AFF995DF83Q34654574-D0C9306B-2EF8-4980-9D6C-24E39BCCCA6AQ35169141-115F630F-D63D-422A-98F7-30B2159F9EB1Q35282145-E69C660A-5D49-4714-A29A-07B29284B13EQ35541040-44B43E0C-7AD0-42BB-BA4F-756353A799B4Q35598795-7AFFD43D-16E8-4E69-A46C-43A6B257021FQ35666205-BC300F32-0A4E-49CD-9E17-B2679C5ECD3FQ35997448-DF3224D9-62D5-4EB2-ACD4-CAEF81D96B29Q36067322-EB2EB1A2-B1AC-4766-ACD1-3767EED5B1E2Q36091234-D31E78D0-6FD3-4686-ACF5-D7944934D039Q36096664-3C41612A-65F6-46FD-B349-61D4E60C559EQ36185585-3BCFA3A4-9B0D-401B-A654-B094D9C38A3BQ36271087-EE80226C-4900-4554-96D5-C0CFB6E88D0FQ36310727-82900C97-4DAE-43B0-8342-76DF8F999884Q36558223-E4EF4332-A80F-4AF0-A48D-EE1944B50908Q36983421-BC782E07-D05C-473B-B60A-53FB654E3602Q37114639-FB15584E-5E2F-4A92-9C94-3369ACB9F9E6Q37363644-0C0DCC4C-D08E-49D5-AC7E-FC07B2F8A55FQ37610768-ADBABE9B-BCF7-4DFC-968F-4951110C005BQ37715559-24492679-7A72-4C4B-BEEA-6136FB69ACEBQ37974998-D8774AE2-0A60-4B95-A81E-44A9BA622BB2Q38072063-BB5BBAF5-97EA-4E5A-A11B-07590FDC5841Q38109593-F06FC720-2F0D-4121-B8B3-477F695DA2CAQ38109852-96AE4BA1-FDC9-45DC-949D-AE04EE5B93C5Q38109864-34BD4CC3-058B-46BC-99F0-93AC8AAA768EQ38123516-8F84438F-533D-49F5-8526-FFD235DA71BCQ38151017-846F4868-977A-47DB-9C0F-21D5C69F82EAQ38151453-136CA819-29AB-4911-A53F-C51076DB3C29
P2860
If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
If at first you don't succeed: ...... tion and switching strategies.
@en
If at first you don't succeed: ...... tion and switching strategies.
@nl
type
label
If at first you don't succeed: ...... tion and switching strategies.
@en
If at first you don't succeed: ...... tion and switching strategies.
@nl
prefLabel
If at first you don't succeed: ...... tion and switching strategies.
@en
If at first you don't succeed: ...... tion and switching strategies.
@nl
P2860
P1433
P1476
If at first you don't succeed: ...... tion and switching strategies.
@en
P2093
K Ryan Connolly
Michael E Thase
P2860
P356
10.2165/11587620-000000000-00000
P577
2011-01-01T00:00:00Z
P6179
1047750138